TBIO: Telesis Bio, Inc. Company Buyout Price

Telesis Bio, Inc (TBIO) - corporate logo

Telesis Bio, Inc. (TBIO) is developing a desktop biomaterial synthesis environment where the BioXp platform significantly accelerates laboratory research. The share price history, featuring the metric, illustrates the complexities of implementing this technology and the pressure from traditional suppliers. The situation is further complicated by persistent losses and a critical liquidity shortage, posing a serious threat to the existence of the entire enterprise.

TBIO Telesis Bio, Inc: Enterprise Value in the range 07/04/2022 - 10/28/2026

Telesis Bio, Inc. (TBIO) - metric breakdowns and financial figures

- price and consensus price forecast:
Price Chart Telesis Bio Inc.|TBIO - Analyst Consensus Forecast
- market capitalization data:
Market Capitalization Telesis Bio|TBIO - Total Company Value
- book capitalization data:
Net Asset Value per Share Telesis Bio|TBIO - Book Capitalization|Capitalization to Book Value Ratio telesisbio.com|TBIO - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Ratio Telesis Bio, Inc.|TBIO - Long-Term Debt to Capital|Short-Term Debt to Capital telesisbio.com|TBIO - Company Total Debt|Debt to Book Capital Telesis Bio
Fundamental company analysis:TBIO (Telesis Bio Inc.)
Original product of Telesis Bio, Inc.

Enterprise value represents the aggregate sum of market capitalization and net debt, reflecting the actual cost of a full business buyout. Analyzing this total operational valuation of Telesis Bio, Inc. (TBIO) allows for a comparison of financial leverage against capital, confirming the market value of Telesis Bio, Inc. (TBIO) as a key developer of automated DNA synthesis systems for personalized medicine.

Direct competitors

Total Company Value Tempus AI TEM|Enterprise Value QGEN (Qiagen Group)|IONS: Company Buyout Price|Total Company Value RGEN|aviditybiosciences.com (RNA) - Total Enterprise Value|Enterprise Value CRISPR Therapeutics (CRSP)|Business Value WGS|Total Company Value Ultragenyx Pharma RARE|Business Value Beam Tx (BEAM)|Enterprise Value SRPT (Sarepta Therapeutics, Inc.)|TWST - Enterprise Value|Real Price to Acquire Entire Company 10x Genomics TXG|NTLA - Aggregate Business Value|Enterprise Value STOK|BLFS (BioLife) - Total Enterprise Value|Total Company Value Wave Life Sciences|Total Company Value mazetx.com|Sionna Therapeutics - Enterprise Value|Total Enterprise Value PRME (Prime Medicine Inc)|Total Company Value TSHA|Company Buyout Price uniQure Pharma QURE|Enterprise Value MGTX (MeiraGTx Holdings plc)|RGNX: Company Buyout Price|Solid Biosciences - Total Company Value|Company Buyout Price Ocugen Inc|PACB - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash Benitec Corp|Enterprise Value Design Therapeutics (DSGN)|Total Company Value rocketpharma.com (RCKT)|Enterprise Value FDMT|Lexeo Therapeutics Inc. - Company Buyout Price|KRRO (Korro Bio, Inc) - Total Company Value|Editas Corp (EDIT) - Total Enterprise Value|Real Price to Acquire Entire Company Silence Therapeutics SLN|ProQR Therapeutics (PRQR) - Value Adjusted for Debt and Cash|CDXS: Enterprise Value|Company Buyout Price SGMO|Total Company Value Nautilus Biotechnology NAUT|Business Value Metagenomi Therapeutics (MGX)|Precision BioSciences, Inc. - Enterprise Value|GBIO - Real Price to Acquire Entire Company|Real Price to Acquire Entire Company BOLD (Boundless Bio)|Exicure, Inc. (XCUR) - Company Buyout Price|IMNN - Real Price to Acquire Entire Company|Phio Pharmaceuticals Corp. (PHIO) - Aggregate Business Value|Enterprise Value Mustang Bio Inc|Total Company Value TransCode|BNGO (Bionano Genomics, Inc.) - Enterprise Value|Company Buyout Price APDN (Applied DNA Sciences Inc)|BLUE: Total Company Value|Total Enterprise Value ImmunoPrecise Antibodies Ltd IPA|Omega Therapeutics (OMGA) - Enterprise Value|OMIC: Business Value|Total Company Value Regulus Therapeutics Inc.|Syros Pharmaceuticals Inc. (SYRS) - Business Value|TCON (TRACON) - Enterprise Value|Enterprise Value Unity Biotechnology, Inc (UBX)